Previous 10 |
Motif Bio (NASDAQ: MTFB ) -75% on receiving CRL from FDA. More news on: Motif Bio, Inovio Pharmaceuticals, Inc., Sierra Wireless, Inc., Stocks on the move, Read more ...
CHICAGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of the Compan...
Gainers: CAS Medical Systems (NASDAQ: CASM ) +54% . Pyxus International (NYSE: PYX ) +23% . Gridsum Holding (NASDAQ: GSUM ) +22% . Ellie Mae (NYSEMKT: ELLI ) +21% . Tronox (NYSE: TROX ) +19% . Select Interior Concepts (NASDAQ: SIC ) +19% . Insignia Systems (NASDAQ: ISIG ) ...
CHICAGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it filed a registrat...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...